“mitch-gold” Archives

in
Entry Author Date Location
Last Chance for “What’s Hot in Cancer Immunotherapy 2017” Tickets 06/12/17 National
Grab Your Ticket for What’s Hot in Cancer Immunotherapy 2017 on June 14th 06/07/17 National
Check Out The Agenda for What’s Hot in Cancer Immunotherapy 2017 05/18/17 National
Bio Roundup: Spinraza Woes, Science March, Baseline Launch & More 04/21/17 National
Ex-Dendreon CEO, Gold, Returns to Wall Street as Alpine, Nivalis Merge 04/18/17 Seattle
Oncorus Bags $57M, Touts Next-Gen Take on Cancer-Fighting Viruses 07/19/16 Boston
Biotech Roundup: Kadmon Debt, Hemo Data, Loose Lips & More 06/17/16 National
As Huge Bills Loom, Immunotherapy Pioneer Dendreon Enters Bankruptcy 11/10/14 Seattle
Former Dendreon CEO Gold Working on New Cancer Drug Startups 10/13/14 Wisconsin
Just 7 Tickets Left for Our What’s Hot in Cancer Event April 22 04/21/14 Seattle
Join Xconomy for ‘What’s Hot in Cancer Immunotherapy’ on April 22 02/20/14 Seattle
Former Dendreon CEO and Dendreon Bull Start New Biotech Hedge Fund 09/03/13 Seattle
Genentech Follows Fast at ASCO as Cancer Immunotherapy Picks Up 05/15/13 San Francisco
Biotech in the Belt-Tightening Era: The Photos 04/12/13 Seattle
See Clay Siegall, Kim Popovits, Mitch Gold This Afternoon 04/09/13 Seattle
Adaptive Biotechnologies Reaches Fork in the Road. What to Charge? 04/03/13 Seattle
How to Make the Payers Pay: Join the Xconomy Event April 9 03/26/13 Seattle
Biotech for the Belt-Tightening Era: Last Chance For Early-Bird Tix 03/12/13 Seattle
Boston Biotech Seizes the Momentum: Last Chance for Early Bird Tix 03/07/13 Boston
Join Us at “Biotech in the Belt-Tightening Era” April 9 in Seattle 02/14/13 Seattle
Third Rock’s Latest, Jounce, Grabs $47M For Cancer Immunotherapy 02/14/13 Boston
Dendreon Shareholders Vent at Annual Meeting 06/13/12 Seattle
Dendreon Surprises With $82M in Fourth Quarter Sales, Stock Booms 01/05/12 Seattle
Dendreon Edges Past Street Expectations With Third Quarter Provenge Sales, Shares Still Fall 11/02/11 Seattle
Dendreon Concentrates Job Cuts in Manufacturing, but Seattle Feels the Axe Too 09/08/11 Seattle
Dendreon Takes Huge Hit, Stock Tanks 60% on Sales Shortfall 08/03/11 Seattle
Dendreon’s Warhorse, Chief Scientific Officer Dave Urdal, To Retire at Year-End 03/11/11 Seattle
Dendreon Scopes Out Downtown Seattle Headquarters 02/18/11 Seattle
Dendreon Plans to Go It Alone in Europe, Build Provenge Factory in Germany 01/07/11 Seattle
See You Tonight at “Biotech’s Back in Seattle” 11/29/10 Seattle
Page 1 of 2 next page »